COMBOGESIC IV Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Combogesic Iv, and when can generic versions of Combogesic Iv launch?
Combogesic Iv is a drug marketed by Hikma and is included in one NDA. There are five patents protecting this drug.
This drug has sixty-five patent family members in thirty countries.
The generic ingredient in COMBOGESIC IV is acetaminophen; ibuprofen sodium. There are sixty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the acetaminophen; ibuprofen sodium profile page.
DrugPatentWatch® Generic Entry Outlook for Combogesic Iv
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 17, 2026. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for COMBOGESIC IV?
- What are the global sales for COMBOGESIC IV?
- What is Average Wholesale Price for COMBOGESIC IV?
Summary for COMBOGESIC IV
International Patents: | 65 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
What excipients (inactive ingredients) are in COMBOGESIC IV? | COMBOGESIC IV excipients list |
DailyMed Link: | COMBOGESIC IV at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for COMBOGESIC IV
Generic Entry Date for COMBOGESIC IV*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for COMBOGESIC IV
Drug Class | Nonsteroidal Anti-inflammatory Drug |
Mechanism of Action | Cyclooxygenase Inhibitors |
US Patents and Regulatory Information for COMBOGESIC IV
COMBOGESIC IV is protected by eight US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of COMBOGESIC IV is ⤷ Sign Up.
This potential generic entry date is based on NEW PRODUCT.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting COMBOGESIC IV
Aqueous formulation comprising paracetamol and ibuprofen
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Combination composition
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING MILD TO MODERATE PAIN IN ADULTS
Combination composition
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING MODERATE TO SEVERE PAIN IN ADULTS AS AN ADJUNCT TO OPIOID ANALGESICS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING MILD TO MODERATE PAIN IN ADULTS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING MODERATE TO SEVERE PAIN IN ADULTS AS AN ADJUNCT TO OPIOID ANALGESICS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING MILD TO MODERATE PAIN IN ADULTS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING MODERATE TO SEVERE PAIN IN ADULTS AS AN ADJUNCT TO OPIOID ANALGESICS
FDA Regulatory Exclusivity protecting COMBOGESIC IV
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hikma | COMBOGESIC IV | acetaminophen; ibuprofen sodium | SOLUTION;INTRAVENOUS | 215320-001 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Hikma | COMBOGESIC IV | acetaminophen; ibuprofen sodium | SOLUTION;INTRAVENOUS | 215320-001 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Hikma | COMBOGESIC IV | acetaminophen; ibuprofen sodium | SOLUTION;INTRAVENOUS | 215320-001 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Hikma | COMBOGESIC IV | acetaminophen; ibuprofen sodium | SOLUTION;INTRAVENOUS | 215320-001 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Hikma | COMBOGESIC IV | acetaminophen; ibuprofen sodium | SOLUTION;INTRAVENOUS | 215320-001 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Hikma | COMBOGESIC IV | acetaminophen; ibuprofen sodium | SOLUTION;INTRAVENOUS | 215320-001 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for COMBOGESIC IV
See the table below for patents covering COMBOGESIC IV around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hungary | E048881 | ⤷ Sign Up | |
Russian Federation | 2013123646 | КОМБИНИРОВАННАЯ КОМПОЗИЦИЯ | ⤷ Sign Up |
Colombia | 6771406 | Una composición combinada | ⤷ Sign Up |
South Korea | 101900520 | ⤷ Sign Up | |
New Zealand | 728796 | Aqueous formulation comprising paracetamol and ibuprofen | ⤷ Sign Up |
Serbia | 59258 | KOMBINOVANA KOMPOZICIJA (A COMBINATION COMPOSITION) | ⤷ Sign Up |
Serbia | 60289 | VODENA FORMULACIJA KOJA SADRŽI PARACETAMOL I IBUPROFEN (AQUEOUS FORMULATION COMPRISING PARACETAMOL AND IBUPROFEN) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |